[1]
Li, L.; Yang, M.; Li, C.; Xue, H.; Shi, M.; Liu, Y. Strategy of Virtual Screening Based Discovery of HSP90 C-terminal Inhibitors and Network Pharmacological Analysis. Curr. Pharm. Biotechnol., 2022.
[2]
Li, J.; Zuo, X.; Cheng, P.; Ren, X.; Sun, S.; Xu, J.; Holmgren, A.; Lu, J. The production of reactive oxygen species enhanced with the reduction of menadione by active thioredoxin reductase. Metallomics, 2019, 11(9), 1490-1497.
[3]
Cheng, P.; Liu, H.; Li, Y.; Pi, P.; Jiang, Y.; Zang, S.; Li, X.; Fu, A.; Ren, X.; Xu, J.; Holmgren, A.; Lu, J. Inhibition of thioredoxin reductase 1 correlates with platinum-based chemotherapeutic induced tissue injury. Biochem. Pharmacol., 2020, 175, 113873.
[4]
Duan, D.; Feng, X.; Pan, D.; Wang, L.; Wang, Y.; Wang, X. Oridonin induces oxidative stress-mediated cancer cells apoptosis via targeting thioredoxin reductase. Curr. Pharm. Biotechnol., 2022.
[5]
Zhang, P.; An, Z.; Sun, C.; Xu, Y.; Zhang, Z. FLG gene mutation up-regulates the abnormal tumor immune response and promotes the progression of prostate cancer. Curr. Pharm. Biotechnol., 2022.
